$412.5 million! Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases

SAN DIEGO, Jan. 19, 2023 /PRNewswire/ — Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced its wholly-owned subsidiary Mabwell Therapeutics has entered into an agreement with DISC MEDICINE, INC. (“Disc”) about 9MW3011 (R&D code…